Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Patients will be followed for 15 years after completion/early termination from the previous TDU13583 study (NCT01367444).
As the initial TDU13583 study is terminated - recruitment to this LTS13588 study is over with 27 patients enrolled.
Age
6–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must meet ALL of the following criteria:
1. Provide signed and dated written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act \[HIPAA\])
2. Must have been enrolled in protocol TDU13583 (SG1/001/10)
3. Must have received a subretinal injection of SAR422459
4. Must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.
You may not be if
The following would exclude Patients from participation in the study:
1\. Did not receive SAR422459 as part of the TDU13583 protocol.
